Brookline Capital Management Estimates Genelux Q1 Earnings

Genelux Corporation (NASDAQ:GNLX) – Analysts at Brookline Capital Management increased their Q1 2026 earnings per share estimates for Genelux in a research note issued to investors on Monday, January 12th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings of ($0.17) per share for the quarter, up from their previous estimate of ($0.20). The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Genelux’s Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.18) EPS and FY2026 earnings at ($0.69) EPS.

Genelux (NASDAQ:GNLX) last issued its earnings results on Wednesday, November 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.02.

Other research analysts also recently issued research reports about the company. Maxim Group set a $20.00 price target on Genelux in a report on Tuesday, October 21st. HC Wainwright reissued a “buy” rating on shares of Genelux in a research note on Monday, January 5th. Lake Street Capital initiated coverage on shares of Genelux in a report on Tuesday, October 21st. They issued a “buy” rating and a $16.00 price target on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Genelux in a report on Wednesday, October 8th. Finally, Loop Capital set a $16.00 target price on shares of Genelux in a research report on Tuesday, October 21st. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Genelux Trading Up 3.4%

GNLX stock opened at $2.74 on Wednesday. The stock has a market capitalization of $104.26 million, a price-to-earnings ratio of -3.11 and a beta of 0.17. The firm’s 50-day moving average price is $4.61 and its two-hundred day moving average price is $4.38. Genelux has a 12-month low of $1.99 and a 12-month high of $8.53.

Institutional Investors Weigh In On Genelux

A number of hedge funds and other institutional investors have recently bought and sold shares of GNLX. Woodward Diversified Capital LLC increased its position in Genelux by 21.7% during the 2nd quarter. Woodward Diversified Capital LLC now owns 1,778,286 shares of the company’s stock valued at $5,104,000 after buying an additional 317,173 shares in the last quarter. Flputnam Investment Management Co. increased its holdings in shares of Genelux by 708.1% during the third quarter. Flputnam Investment Management Co. now owns 300,290 shares of the company’s stock valued at $1,261,000 after acquiring an additional 263,131 shares in the last quarter. MAI Capital Management raised its position in shares of Genelux by 66,161.3% in the 2nd quarter. MAI Capital Management now owns 236,553 shares of the company’s stock worth $679,000 after purchasing an additional 236,196 shares during the last quarter. Global Retirement Partners LLC bought a new position in Genelux in the 2nd quarter worth about $656,000. Finally, Osaic Holdings Inc. grew its position in Genelux by 1,911.4% during the 2nd quarter. Osaic Holdings Inc. now owns 105,016 shares of the company’s stock valued at $301,000 after purchasing an additional 99,795 shares during the last quarter. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Insider Activity

In related news, Director John Thomas sold 10,000 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $5.00, for a total value of $50,000.00. Following the completion of the transaction, the director directly owned 492,784 shares in the company, valued at $2,463,920. This trade represents a 1.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders have sold 15,990 shares of company stock valued at $82,054. 8.80% of the stock is owned by company insiders.

About Genelux

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.